Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 27

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 27
---
 the year ended December 31, 2024, was $7,178,333, representing an increase of $3,923,910 compared to a net loss of $3,254,423 for the year ended December 31, 2023. The increase is primarily due to increase in non -cashrevaluation of derivative loans from related parties, partly offset by decrease in general and administrative expenses and research and development expenses as part of the efficiency program as described above. Liquidity and Capital Resources Kadimastem is a research and development entity that funds its operations through capital raising, convertible loans, loans from interested parties, and national and international research grants. To enhance its exposure to capital markets, Kadimastem often engages external consultants. Since Kadimastem’s inception, it has financed its operations primarily through the sale of equity securities, debt financing, convertible loans and royalty -bearinggrants that Kadimastem has received from the Israel Innovation Authority. Kadimastem’s primary requirements for liquidity and capital are to finance working capital, capital expenditures and general corporate purposes. Kadimastem has incurred significant losses and negative cash flows from operations. Net loss was $11,204,458 (of which $9,957,470 was due to derivative financial expenses) and $1,236,329 for the six months ended June 30, 2025, and June 30, 2024, respectively. During the six months ended June 30, 2025, and June 30, 2024, Kadimastem had negative cash flows from operations of $602,695 and $763,677, respectively. As of June 30, 2025, Kadimastem’s accumulated deficit was $87,734,255. Kadimastem has funded its operations to date through equity and debt financing and had cash on hand (including short -termbank deposits) of $298,932 as of June 30, 2025. Kadimastem’s net loss during the fiscal years ended December 31, 2024, December 31, 2023 was $7,178,333, and $3,254,423, respectively. During the fiscal years ended December 31, 2024, and December 31, 2023, Kadimastem had negative cash flows from operations in the amount of $705,483, and $2,995,813, respectively. As of December 31, 2024,